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This work proposes that the combination of defective
homing and reduced intrinsic regulatory T cell function
synergize to reduce regulatory T-cell function sufficiently in
the gut to counteract the protective effect of b7 deficiency
on homing of conventional T cells, thus exacerbating intes-
tinal inflammation.
BACKGROUND & AIMS: Integrin a4b7 mediates lymphocyte
trafficking to the gut and gut-associated lymphoid tissues, a
process critical for recruitment of effector lymphocytes from
the circulation to the gut mucosa in inflammatory bowel
disease (IBD) and murine models of intestinal inflammation.
Antibody blockade of b7 integrins generally is efficacious in
IBD; however, some patients fail to respond, and a few pa-
tients can experience exacerbations. This study examined the
effects of loss of b7 integrin function in murine models of IBD.
METHODS: In a mouse IBD model caused by lack of interleukin
10, a cytokine important in CD25hiFoxP3þ regulatory T cell
(Treg) function, genetic deletion of b7 integrin or antibody
blockade of a4b7–mucosal addressin cell adhesion molecule-1
interaction paradoxically exacerbated colitis.
RESULTS: Loss of b7 impaired the capacity of Tregs homing
to the gut and therefore suppress intestinal inflammation in
an adoptive T-cell transfer model; however, the intrinsic
suppressive function of b7-deficient Tregs remained intact,
indicating that the b7 deficiency selectively impacts gut
homing. Deletion of b7 integrin did not worsen colitis in an
acute dextran sodium sulfate model in which Treg number
and function were normal.
CONCLUSIONS: In Integrin subunit beta (Itgb)7-/-Il10-/- mice,
loss of b7-dependent Treg homing to gut-associated lymphoid
tissues combined with loss of intrinsic Treg function exacer-
bated intestinal inflammation. These results suggest that IBD
patients with reduced CD25hiFoxP3þ Treg numbers or function
or lack of interleukin 10 could be at risk for failure of a4b7
blocking therapy. (Cell Mol Gastroenterol Hepatol
2020;9:369–385; https://doi.org/10.1016/j.jcmgh.2019.10.012)
Keywords: Integrin b7 Blockade; Inflammatory Bowel Disease;
Regulatory T Cells; Gut-Associated Lymphoid Tissue.omeostasis in the gut relies on a fine-tuned inter-Hplay of protective immunity against pathogens
while maintaining tolerance to the commensal microbiota
that comprises much of the intestinal microenvironment.
Disruption of homeostasis can lead to intestinal disorders
such as inflammatory bowel disease (IBD).1–4 A key feature
of the inflammatory response in IBD is the rapid recruit-
ment of leukocytes from the blood stream to the intestine
via cell adhesion and transmigration through blood vessel
walls,5–7 leading to massive infiltration of mononuclear
phagocytes, neutrophils, and inflammatory T cells into the
intestinal lamina propria.8–10
Leukocyte homing to the gut is regulated by a network of
adhesion molecules and their ligands to ensure the proper
location of immune cells for interaction with the local micro-
environment.11 This process is controlled largely by chemo-
kines, which initiate a multistep adhesion cascade involving
tethering, rolling, and cell arrest12,13 through modulation of
integrin binding to endothelial andmucosal ligands (eg, aLb2/
intercellular adhesion molecule-1[ICAM-1], a4b1/vascular
cell adhesion molecule-1[VCAM-1], and a4b7/mucosal
addressin cell adhesion molecule-1 [MAdCAM-1]).
Blockade of mucosal T-cell homing is a therapeutic
approach for IBD.14 Integrin a4b7, which is expressed on the
surface of gut-tropic effector lymphocytes, is an important cell
adhesionmolecule thatmediates lymphocyte trafficking to gut
and gut-associated lymphoid tissue (GALT). Vedolizumab,
which specifically blocks integrina4b7, is used for attenuating
mucosal inflammation in patients with Crohn’s disease (CD)
and ulcerative colitis (UC).15,16 Despite the general effective-
ness of vedolizumab, a significant number of IBD patients are
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because of a lack or loss of response in 36%–54% of IBD pa-
tients.17,18 Moreover, high doses of etrolizumab, which blocks
b7 integrins (ie, a4b7, aEb7), is associated with a reduced
clinical response.19 Thus, although b7 blockade generally is
beneficial in IBD, the reason that some patients are non-
responders remains unclear.
CD25hiFoxp3þ regulatory T cells (Tregs) can limit the
development of colitis by reducing the accumulation and
activity of effector cells in the inflamed mucosa.20–24 Tregs
can suppress immune responses by a wide variety of mech-
anisms, including secretion of immunosuppressive cytokines
such as interleukin (IL)10.25 IL10 is a major immunosup-
pressive product of Tregs to maintain homeostasis at the
environmental interface of the intestine.26 In addition, IL10-
deficient mice develop spontaneous IBD.27,28 Recent work
has indicated that a4b7 is crucial for homing of Tregs to gut
and GALT in patients with UC,29 and b7 deficiency causes a
reduction of murine Tregs in the gut.30,31 Here, we report
that IL10-deficient mice, which are deficient in the Treg
function of IL10 secretion, paradoxically developed exacer-
bated intestinal inflammation when b7 was genetically
inactivated or a4b7-mediated gut homing was blocked by
antibodies. These effects of loss of b7 function were associ-
ated with a loss of Tregs in the lamina propria owing to
reduced Treg homing to the gut. By using an adoptive transfer
model of intestinal inflammation, we show that b7-deficient
Tregs are impaired in their capacity to populate the lamina
propria and to prevent intestinal inflammation even though
they show normal intrinsic suppressive functions. Taken
together, these data suggest that the combination of reduced
Tregs function in IL10 null mice and reduced Treg homing
secondary to loss of b7 function, in combination, reduce Treg
activity in the gut sufficiently to counteract the protective
effect of blocking b7 homing of conventional T cells (Tconv).
This conclusion implies that the presence of reduced Treg
number or function or reduced IL10 expression could pre-
dispose to impaired efficacy of b7 blockade in IBD.
Results
b7 Deficiency Exacerbates Spontaneous Colitis
in Il10-/- Mice
Integrin a4b7 mediates trafficking of Tconv to gut and
GALT and antibody blockade of a4b7 benefits many patients
with either CD or UC.15,16 To assess the role of b7 integrin in
the development of chronic intestinal inflammation in a
mouse model, we used an IL10-deficient mouse strain
(B6.129P2-Il10tm1Cgn/J) that develops chronic colitis
resembling IBD in human beings.27,28 IL10-deficient mice
were crossed with b7-deficient mice, and the phenotypes of
Integrin subunit beta (Itgb)7-/-Il10-/- mice were compared
with Itgb7þ/þIl10-/- mice.
As expected,27,28 Itgb7þ/þIl10-/- mice spontaneously
developed diarrhea beginning at the age of 60–70 days under
specific pathogen-free conditions in our animal facility. On
average, the mice did not lose weight; however, 6 of 22 mice
died by 70 days (Figure 1B), and 7 of 22mice developed rectal
prolapse. Unexpectedly, b7 deficiency exacerbated disease inIl10-/-mice as judged by dramatic weight loss accompanied by
severe diarrhea and rectal bleeding (Figure 1A and C).
Furthermore, Itgb7-/-Il10-/- mice almost uniformly developed
rectal prolapse (Figure 1D) and more than two thirds of them
died by approximately 70 days (Figure 1B). Itgb7-/-Il10-/-mice
were more anemic than integrin b7–replete Itgb7þ/þIl10-/-
animals (Figure 1E). The exacerbated colitis in Itgb7-/-Il10-/-
mice was confirmed by significantly increased crypt distor-
tion, mucosal ulceration, and infiltration of immune cells,
compared with Itgb7þ/þIl10-/- mice (Figure 1F and G). In
addition, colonic expression of proinflammatory cytokines
was increased significantly in Itgb7-/-Il10-/- mice compared
with Itgb7þ/þIl10-/- mice (Figure 2).
To assess the contribution of b7 integrin further in
mediating leukocyte recruitment and subsequent damage to
the gut mucosa, we used piroxicam administration as a
method to synchronize development of colitis in IL10-
deficient mice.32 We administered piroxicam to IL10-null
mice orally for 2 weeks. By 35 days after piroxicam initia-
tion, approximately 80% of Itgb7-/-Il10-/- mice died. In
contrast, only approximately 28% of Itgb7þ/þIl10-/- mice
died (Figure 1H). Thus, b7 deficiency exacerbated both
spontaneous and induced IBD in IL10-deficient mice, a
surprising result in light of the benefits of blockade of a4b7
in many IBD patients.Integrin b7 Deficiency Results in Decreased
Tregs in the Colon
Integrin a4b7 mediates lymphocyte trafficking to the
intestinal mucosa by binding to its ligand, MAdCAM-1. To
investigate whether the severe colitis in Itgb7-/-Il10-/- mice
was associated with reduced colonic Tregs, we enumerated
Tregs and conventional CD4þ T cells in the colonic lamina
propria. Itgb7-/-Il10-/- mice showed approximately 75%
reduced Tregs in the colonic lamina propria compared with
Itgb7þ/þIl10-/- mice (Figure 3), consistent with observa-
tions in other models.29–31 In contrast, a slight but statis-
tically significant increase (P ¼ .02) in the number of
colonic lamina propria CD4þ T cells in Itgb7þ/þIl10-/- mice
was observed, resulting in an approximately 80% reduc-
tion of Tregs as a percentage of colonic lamina propria
CD4þ T cells (Figure 3A and B). The abundance of Tregs
and total CD4þ T cells in the spleen was not significantly
different between Itgb7-/-Il10-/- mice and Itgb7þ/þIl10-/-
mice (Figure 3A and B), indicating that Tregs generally
were not reduced in the absence of b7. A similar reduction
in colonic lamina propria Tregs was observed in piroxicam-
treated Itgb7-/-Il10-/- mice (Figure 3C). Importantly,
expression of canonical Treg markers CD25 and Foxp3 was
similar in Itgb7-/-Il10-/- mice and Itgb7þ/þIl10-/- mice
(Figure 4). Furthermore, a wide variety of other Treg-
associated proteins including OX40, CD152, T-bet, GATA3,
and KLRG1 were expressed at similar levels in Tregs from
spleen and lamina propria of Itgb7-/-Il10-/- mice and
Itgb7þ/þIl10-/- mice (Figure 5). As expected, CD103 (aE),
which requires pairing with b7, is not expressed in Itg-
b7-/-Il10-/- Tregs (Figure 5). In sum, these data show that
integrin b7 deficiency results in a profound reduction of
2020 Tregs Modify Response to a4b7 Inhibition 371colonic Tregs in Itgb7-/-Il10-/- mice. Moreover, the number
of Tregs in mesenteric lymph nodes (MLNs) also was
reduced significantly in Itgb7-/-Il10-/- mice. However, theA B
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Figure 4. CD25 and
Foxp3 expression on
Itgb7-/- Tregs. Expression
ofCD25andFoxp3onTregs
from Itgb7þ/þFoxp3GFP or
Itgb7-/-Foxp3GFP mice are
shown. Splenocytes were
stained with CD25 antibody
and then analyzed by flow
cytometry.
2020 Tregs Modify Response to a4b7 Inhibition 373of Tregs in GALT; however, with the exception of aEb7, b7-
null Tregs that enter the colon express a typical repertoire
of Treg-associated markers and transcription factors.Integrin b7–Deficient CD4þ T Cells Ameliorate
Adoptive T-Cell–Transfer–Induced Colitis
The foregoing results led us to ask whether the delete-
rious effects of loss of b7 function were mediated by effects
on Tconv or Tregs. To investigate the role of b7 in Tconv
cells and their capacity to induce colitis, we transferred
CD4þCD25-CD45RBhigh T cells (Tconv cells) from wild-type
(WT) mice or Itgb7-/- mice into Rag1-/- recipient mice.
Rag1-/- mice injected with WT Tconv cells showed a dra-
matic loss in body weight starting at 20–30 days, and one
third of the mice died by 90 days (Figure 7A and B). In
contrast, Rag1-/- mice injected with Itgb7-/- Tconv cells
showed a significantly milder and delayed weight loss
compared with WT Tconv cells and most of the mice sur-
vived (Figure 7A and B).
We next tested the role of integrin b7 on CD4þ T-cell
migration using the competitive homing assay. b7-deficient
CD4þ T cells were impaired for homing to MLNs and Pey-
er’s patch (PP), but not PLNs and spleen (SP) (Figure 7C),
which is consistent with previous studies.33 Thus, b7-
deficient CD4þ T cells manifest a defective migration to the
colon, which reduces adoptive T-cell–transfer–induced colitis.Integrin b7-Deficient Tregs Are Defective in the
Capacity to Prevent Colitis
We examined the effect of b7 deficiency on the ability of
Tregs to prevent intestinal inflammation in the adoptive T-
cell transfer model.34 Transfer of CD4þCD25-CD45RBhigh T
cells (CD4þ Tconv) into Rag1-/- mice led to a severe colitis
by 6–12 weeks after cell transfer. Loss of body weight
started after 20 days (Figure 8A), and half of the mice had
died by 90 days (Figure 8B). As expected, co-injection ofItgb7þ/þ Tregs with Tconv prevented colitis (Figure 8A and
B), whereas injection of Itgb7-/- Tregs with Tconv did not
prevent disease. At 90 days, the disease markers in the mice
receiving co-administered b7-deficient Tregs was similar to
that of those receiving only Tconv (Figure 8C and D).
Moreover, expression of proinflammatory cytokines in the
colon was not significantly different in mice receiving
Itgb7-/- Tregs compared with Tconv alone, whereas those
that had received Itgb7þ/þ Tregs showed only minimal
cytokine expression (Figure 8E). These results show that b7
deficiency impairs the capacity of Tregs to prevent adoptive
T-cell–transfer–induced colitis, whereas it impairs the ca-
pacity of Tconv to cause colitis.
Defective Suppression of Colitis in b7-Deficient
Tregs Is Ascribable to Defective Homing
To evaluate the possibility that integrin b7-deficient
Tregs lacked suppressive capacity we examined their abil-
ity to inhibit T-cell proliferation. Green fluorescent protein
positive (GFPþ) Tregs were sorted from Itgb7þ/þFoxp3GFP
or Itgb7-/-Foxp3GFP mice and their capacity to suppress
proliferation of CD4þCD25- responder cells was compared
in a dye dilution assay. Carboxyfluorescein succinimidyl
ester (CFSE)-labeled responder cells stimulated with
immobilized anti-CD3 and anti-CD28 in the presence of IL2
for 4 days at 37C proliferated vigorously as indicated by
the dilution of fluorescence (Figure 9A). The addition of a
1:1 ratio of b7-deficient or replete Tregs markedly reduced
proliferation in these cultures (Figure 9A). The proliferation
index as a function of Treg/responder ratio was not signif-
icantly different between cultures with Treg lacking b7 and
those sufficient for b7 (Figure 9B). Furthermore, b7-
deficient Tregs showed similar expression of the anti-
inflammatory cytokines IL10 and transforming growth
factor (TGF)-b1 as wild-type Tregs (Figure 9C). Thus, b7-
deficient Tregs are functionally intact with regard to their
suppressive functions.
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Figure 5. Treg markers
and transcription factor
expression on Itgb7-/-
Tregs. Expression of Treg
markers CD103, CD152
(CTLA4), OX40, and
KLRG1, as well as tran-
scription factors T-bet and
GATA3, are shown. Cells
from (A) spleen and (B)
colonic lamina propria
were isolated, stained with
the indicated antibody,
and then analyzed by flow
cytometry.
374 Sun et al Cellular and Molecular Gastroenterology and Hepatology Vol. 9, No. 3The failure of Itgb7-/- Tregs to efficiently suppress colitis
despite normal intrinsic suppressive function suggested that
defective homing of Itgb7-/- Tregs may explain their reduced
capacity to block colon inflammation. To test this idea, we
used a competitive homing assay with GFPþ Tregs isolated
from Itgb7þ/þFoxp3GFP or Itgb7-/-Foxp3GFP mice, labeled
them with a 1 mmol/L and 10 mmol/L concentration of
eFluor670 proliferation dye, respectively, and co-injected
equal numbers (1  107) of differentially labeled cells
into recipient mice. Lymphoid organs were harvested 3
hours after injection, and cells were isolated and analyzed
by flow cytometry. Similar to the known effects of deficiency
on Tconv homing (Figure 7C), b7-deficient Tregs homing to
PP was reduced by approximately 90% compared with b7-
sufficient cells, whereas homing to MLN was reduced
modestly (w50%). In contrast, homing of Tregs to PLN and
SP were similar in Itgb7-/- and Itgb7þ/þ Tregs (Figure 9D).The absolute cell numbers of both WT or Itgb7-/- Tregs in
the different organs also were checked (Figure 10). Thus,
there is a profound reduction in Tregs in the GALT of Itgb7-/-
mice that is attributable, at least in part, to defective homing
of these cells, and this reduction can account for the exac-
erbation of colitis on an Il10-/- background.b7 Deficiency Does Not Exacerbate Acute
Dextran Sulfate Sodium–Induced Colitis
Increased colitis in Itgb7-/-Il10-/- mice seemed paradoxic
in light of the therapeutic efficacy of a4b7 blockade in IBD
patients. We reasoned that the combination of reduced
functionality of Tregs lacking IL10 combined with a reduc-
tion of Tregs in the GALT of b7-deficient mice might syn-
ergistically reduce Treg function in the gut sufficient to
exacerbate colitis. To test this idea, we examined the effect
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Figure 7. b7-deficient CD4D T cells ameliorate adoptive T-
cell–transfer–induced colitis. (A and B)
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or Itgb7-/- mice were injected into Rag1-/- mice. Changes in
(A) body weight and (B) survival ratio are shown. Changes in
body weight are shown as a percentage of the original
weight. The number of mice in each group is indicated. Data
represent means ± SEM. Two-way analysis of variance with
the Bonferroni posttest. (C) In vivo competitive homing of
CD4þ T cells to lymphoid tissues. CD4þ T cells were isolated
from either Itgb7þ/þ or Itgb7-/- mice, differentially labeled, and
mixed before injection into C57BL/6 mice. CD4þ T cells
homing to different lymphoid organs were analyzed by flow
cytometry 3 hours after injection. The ratio of Itgb7-/- CD4þ T
cells to Itgb7þ/þ CD4þ T cells (Itgb7-/-/WT) from different
lymphoid organs is shown (n ¼ 14). Data represent means ±
SEM. One-way analysis of variance with the Bonferroni
posttest. **P < .01. WT Tconv, Tconv cells from Itgb7þ/þ
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2020 Tregs Modify Response to a4b7 Inhibition 375of b7 deficiency in a colitis model in which Treg function
was normal. We administered dextran sulfate sodium (DSS)
for 7 days and then analyzed the mice for an additional 7
days, times at which inflammation is dominated largely by
the innate immune response to bacterial products that
breach the intestinal barrier as a consequence of mucosal
injury.31,35 Subsequently, an adaptive immune component
can contribute to further chronic inflammation,36 thus
potentially accounting for the finding by Zhang et al that b7
deficiency exacerbated a later stage of DSS colitis.28 Both
Itgb7þ/þ and Itgb7-/- mice showed similar rapid body
weight loss during the initial phase of DSS treatment. Once
DSS administration was halted, Itgb7-/- mice gained weight
slightly but significantly more rapidly than Itgb7þ/þ mice
(Figure 11A). Itgb7-/- mice showed less mucosal immune
cell infiltration and crypt destruction (Figure 11B), as
shown by lower histologic scores (Figure 11C), and further
supported by less anemia (Figure 6D). Thus, in sharp
contrast to the IL10-deficient model, b7 deficiency did not
exacerbate inflammation in this acute DSS model of colitis.
Antibody Blockade of a4b7–MAdCAM-1
Interaction Aggravates Spontaneous Colitis
Induced by IL10 Deficiency
The foregoing studies showed that genetic inactivation of
integrin b7 exacerbated colitis in Itgb7-/-Il10-/- mice and
ascribed the exacerbation to a combination of reduced Treg
function and homing to GALT. These results raise 2 important
issues: (1) b7 can combine with aE or a4; can loss of only
a4b7 function exacerbate colitis in IL10-null mice? (2) Itgb7-/-
mice lack b7 function throughout development: will loss of
a4b7 function in an adult IL10-deficient mouse exacerbate
colitis? MAdCAM-1, which is expressed preferentially on gut
and GALT-associated endothelial cells, plays a vital role in
a4b7-mediated leukocyte trafficking to the GALT and is a
primary ligand of integrin a4b7. Because we did not have
access to a function blocking antimurine a4b7, Il10-/- mice
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376 Sun et al Cellular and Molecular Gastroenterology and Hepatology Vol. 9, No. 3were treated with a MAdCAM-1 blocking antibody, MECA367,
which inhibits binding of a4b7 integrin to MAdCAM-137 and
ameliorates DSS-induced colitis.38,39 MECA367-treated Il10-/-
mice showed profound weight loss and shorter survival
compared with control IgG-treated Il10-/- mice (Figure 12A
and B). Furthermore, MECA367-treated Il10-/- mice showed
more severe anemia (Figure 12C) and increased inflammation
and colonic tissue injury (Figure 12D and E) compared with
control IgG-treated Il10-/- mice. Thus, blocking the interaction
between MAdCAM-1 and integrin a4b7 in vivo aggravates
spontaneous colitis induced by IL10 deficiency.Discussion
Leukocyte homing to GALT has complex roles in the
pathogenesis of IBD.15,40–42 Antibodies against b7 integrins,
which inhibit leukocyte trafficking to the gut and GALT, are
not uniformly efficacious at ameliorating IBD.15 Here, wereport that mice lacking IL10, a major immunosuppressive
cytokine of Tregs, unexpectedly developed increased in-
testinal inflammation when b7 was genetically inactivated
or a4b7-mediated GALT homing was blocked by anti-
bodies. These effects of loss of b7 function were associated
with reduced Tregs in the lamina propria owing to
impaired Treg homing to the gut. In an adoptive transfer
model of intestinal inflammation, we found that b7-
deficient Tregs are impaired in their capacity to colonize
GALT and to oppose intestinal inflammation despite pos-
sessing normal intrinsic suppressive functions. We propose
that the combination of reduced Treg function in IL10-null
mice and reduced Treg homing owing to loss of b7 func-
tion, in combination, decrease net Treg suppressive activity
in the gut sufficiently to counteract the protective effect of
blocking b7 on homing of conventional T cells. Thus, Treg
numbers or functions could affect the efficacy of b7
blockade in IBD (Figure 13).
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2020 Tregs Modify Response to a4b7 Inhibition 377Surprisingly, loss of b7 function in mice lacking IL10
caused increased intestinal inflammation. Genetic b7 defi-
ciency aggravated spontaneous colitis in IL10-deficient mice
as judged by dramatic body weight loss accompanied by
severe diarrhea and rectal bleeding. These symptoms were
associated with histologic evidence of increased tissue
damage and inflammation, worsened anemia, and increased
colonic expression of proinflammatory cytokines. Impor-
tantly, because we were obliged to breed Il10-/- mice through
crosses of Il10þ/- mice, it was not feasible to generate suf-
ficient numbers of littermate Itgb7-/-Il10-/- and Itgb7þ/þ
Il10-/- controls. Because b7 deficiency can impact the intes-
tinal flora,43 even though b7-null and WT mice were on a
C57 BL/6 background and were cohoused, it is possible that
some of the effects of b7 deficiency could be the result of an
altered microbiome. That said, Il10-/- mice experienced a
similar worsening of colitis after antibody blockade of
a4b7–MAdCAM-1 interaction in comparison with cohoused
IgG-treated littermates. Furthermore, in the adoptive trans-
fer model of colitis, we documented that b7-null Tregs were
defective in suppressing intestinal inflammation compared
with WT Tregs when administered to cohoused littermatemice. These results sharply contrast with the beneficial ef-
fects of a4b7-blocking antibody in patients with active UC or
CD.15,16 Earlier studies in mice also reported that inhibiting
b7-integrin function attenuated acute and chronic murine
models of intestinal inflammation.44,45 Thus, loss of b7
integrin function causes increased intestinal inflammation in
IL10-deficient mice despite its often beneficial effects in
other murine models and in human beings with IBD.
Vedolizumab blocks integrin a4b7 on both effector T
cells and Tregs. Recent studies have reported that a4b7 is
crucial for controlling homing of Tregs in patients with UC
to the inflamed colon in vivo,29 and b7 deficiency causes
Treg depletion in the gut.30,31 Nevertheless, our data suggest
that combined loss of Treg function and b7-dependent Treg
homing to gut and GALT together can counteract a protec-
tive effect of b7 blockade of effector T-cell migration on
intestinal inflammation. Integrin Itgb7-/- Tregs were defec-
tive in their capacity to prevent induction of colitis in
immune-deficient mice reconstituted with Tconv. We note
that Denning et al reported that Itgb7-/- Tregs could prevent
colitis in their adoptive transfer model, a difference that
might be a consequence of their use of a different
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Inflammation
Effector T cells Regulatory T cells
Integrin 7 deficiency
Figure 13. Schematic diagram of b7 function in gut
inflammation. During gut inflammation, a disrupted protective
mucus layer and epithelial barrier leads to increased uptake of
luminal bacteria. Bacterial antigens result in the activation of
immune cells such as T cells and macrophages, with the
consequent release of proinflammatory cytokines, with further
recruitment of leukocytes. b7 blockade suppresses effector T-
cell migration to the gut, thereby ameliorating inflammation.
However, it additionally reduced Treg homing to the gut,
counteracting their anti-inflammatory activity.
2020 Tregs Modify Response to a4b7 Inhibition 379immunodeficient recipient mouse strain.30 Because Itgb7-/-
Tregs manifested intact suppressor function in vitro, this
defect likely was owing to their reduced ability to populate
the gut and GALT, a reduction we can ascribe to reduced
migration to the GALT as shown in competitive homing
experiments. Furthermore, vedolizumab can block the
homing of Tregs from UC patients to the inflamed gut.29
IL10 is a product of Tregs that is essential for the
maintenance of intestinal homeostasis. It suppresses
effector functions of T helper (Th)1/Th17 cells as well as
natural killer cells and macrophages, thereby modulating
both innate and adaptive immune responses46 and muting
pathogenic Th17 responses to pathobionts.47 Tregs are a
major source of IL10 to maintain homeostasis at the envi-
ronmental interface of the intestine.26 Thus, reduced hom-
ing of Itgb7-/- Tregs to gut and GALT, combined with a lack
of IL10, together will profoundly reduce Treg suppression of
inflammation in the colon. In contrast, Itgb7-/- mice did not
experience an exacerbation of the acute DSS model in which
Treg function was not impaired. IBD can have a variety of
underlying causes such as defects in the NACHT, LRR and
PYD domains-containing protein 3 (NLRP3) inflamma-
some48 or defective Tregs. We show that reduced integrin
b7–mediated homing in the setting of reduced loss of IL10
exacerbates intestinal inflammation. Thus, loss of IL10
expression or reduced Treg numbers or functions in
380 Sun et al Cellular and Molecular Gastroenterology and Hepatology Vol. 9, No. 3patients with IBD may impact their response to therapeutic
inhibition of b7 integrins.
Materials and Methods
Antibodies and Reagents
The following antibodies were from BioLegend (San
Diego, CA): CD4 (GK1.5), b7 (FIB504), Foxp3 (MF-14), anti-
CD3 (2C11), anti-CD28 (37.51), IL10 (JES5-16E3), TGF-b1
(TW7-16B4), and anti–MAdCAM-1 (MECA367). Secondary
AlexaFluor-labeled antibodies were from Jackson Immu-
noResearch (West Grove, PA). The Foxp3 transcription fac-
tor fixation/permeabilization kit was purchased from
eBioscience. CFSE and eFluor670 were purchased from
Invitrogen (Carlsbad, CA) and BioLegend, respectively. Pir-
oxicam was from MilliporeSigma (Burlington, MA). Ion-
omycin, brefeldin A, and monensin were from BioLegend.
The MojoSort mouse CD3 T-cell isolation kit and mouse CD4
T-cell isolation kit were from BioLegend. Liberase TL
(research grade) and DNAse I were from Roche (Basel,
Switzerland). Recombinant mouse MAdCAM-1–Fc was pu-
rified by protein A beads as previously described.49
Mice
All animal experiments were approved by the Institu-
tional Animal Care and Use Committee of the University of
California San Diego, and were conducted in accordance
with federal regulations as well as institutional guidelines
and regulations on animal studies. All mice were housed in
specific pathogen-free conditions on corncob bedding and
were fed ad libitum with a chow diet. C57BL/6 (CD45.1),
C57BL/6 (CD45.2), Itgb7-/-, Il10-/-, Rag1-/- mice were from
The Jackson Laboratory (Bar Harbor, ME). Foxp3GFP mice
have been described previously.26,50 All of the mice were on
a C57BL/6 background. For experiments, 8- to 12-week-old
mice were used. All injections of antibodies, control IgG,
Tconv, and Tregs were performed during the light cycle.
Mononuclear cells were isolated from MLN, PP, PLN, SP,
and colonic lamina propria as previously described.13,51 Cell
counting with immunofluorescence cytometry was per-
formed using an Accuri C6 Plus and FACSCalibur (BD Bio-
sciences, San Diego, CA).Mouse Colitis Models
Il10-/- mice spontaneously develop chronic IBD under
specific pathogen-free conditions. The phenotypes of
chronic colitis in Il10-/- mice (C57BL/6 genetic background)
became more evident at 10–12 weeks. Because Il10-/- mice
develop spontaneous colitis, which has negative conse-
quences on their capacity to breed, we separately crossed
the mice as Itgb7þ/þIl10þ/-  Itgb7þ/þIl10þ/- and
Itgb7-/-Il10þ/-  Itgb7-/-Il10þ/- to generate Itgb7þ/þIl10-/-
and Itgb7-/-Il10-/-, respectively. Sex-matched Itgb7þ/þIl10-/-
and Itgb7-/-Il10-/- mice were cohoused starting at 3-4 weeks
after weaning. For piroxicam treatment, mice were admin-
istered piroxicam (200 ppm in their diet everyday) for 2
weeks and killed 3 weeks after the end of piroxicam treat-
ment.32 For the adoptive T-cell–transfer model, 8- to 10-
week-old mice were used. CD4þCD25-CD45RBhighconventional T cells (5  105) from C57BL/6 mice were
injected intraperitoneally into cohoused Rag1-/- mice in the
presence or absence of 1  105 CD4þCD25þCD45RBlow
Tregs derived from the indicated mutant genotype litter-
mate mice (0.2 mL phosphate-buffered saline each recip-
ient). In acute colitis experiments, cohoused Itgb7þ/þ or
Itgb7-/- littermates were administered 1.5% (wt/vol) DSS
with a molecular mass of 36–50 kilodaltons (MP Bio-
medicals, Irvine, CA) in drinking water for a total of 7 days
(days 0–7), followed by plain drinking water (days 8–14).
Mice were assessed daily for body weight, diarrhea, and
bloody stool. The disease activity index and histologic
damage were assessed by trained individuals blinded to the
treatment groups, as reported previously.31 For anti-
–MAdCAM-1 blocking antibody MECA367 treatment, the
Il10-/- cohoused littermates were injected intraperitoneally
with MECA367 or control IgG (100 mg/mouse) every 4 days.
Mice were euthanized, and peripheral blood was collected
to test hemoglobin levels. Colons were isolated for histology
and quantitative polymerase chain reaction (PCR) analysis.
Mouse body weight was measured every day and values
are shown as a percentage of the original weight. During the
duration of the experiment, we assessed the clinical pro-
gression of colitis by daily scoring a disease activity index.
The disease activity index is the combined score of body
weight loss, stool consistency, and rectal bleeding and pro-
lapse, as follows: (1) weight loss: 0 (no loss), 1 (1%–5%), 2
(5%–10%), 3 (10%–20%), and 4 (>20%); (2) stool con-
sistency: 0 (normal),1 (soft), 2 (very soft), and 3 (diarrhea);
(3) rectal bleeding: 0 (none), 1 (red), 2 (dark red), and 3
(gross bleeding); and (4) rectal prolapse: 0 (none), 1 (signs
of prolapse), 2 (clear prolapse), and 3 (extensive prolapse).
Mice were killed at week 15.
Histology
Formalin-fixed, paraffin-embedded, Swiss-rolled colon
sections of 4-mm thickness were mounted on glass slides
and followed by H&E staining or periodic acid–Schiff
staining. Images were acquired with a Nanozoomer Slide
Scanner (Hamamatsu Nanozoomer 2.0 HT Slide Scanner,
Hamamatsu City, Japan). Blinded histologic scoring was
performed by 2 investigators based on the method
described previously.52 Two different scoring schemes were
used (Tables 1 and 2).
Flow Cytometry
Cells isolated from mouse tissues were washed and
resuspended in Hank’s balanced salt solution containing
0.1% bovine serum albumin and 1 mmol/L Ca2þ/Mg2þ and
stained with conjugated antibody for 30 minutes at 4C.
Then cells were washed twice before flow cytometry anal-
ysis using an Accuri C6 Plus or FACSCalibur (BD Bio-
sciences). Data were analyzed using FlowJo software
(FlowJo, Ashland, OR). For intracellular detection of cyto-
kines, splenocytes were stimulated ex vivo with Phorbol 12-
myristate 13-acetate and ionomycin in the presence of
brefeldin A and monensin for 6 hours at 37C; cells were
fixed in 4% paraformaldehyde (Electron Microscopy
Table 1.Scoring Scheme for Il10 Mice Model
Epithelium (0–6)
0 Normal
1 Hyperproliferation, irregular crypts, goblet cell loss
2 Mild to moderate crypt loss (10%–50%)
3 Severe crypt loss (50%–90%)
4 Complete crypt loss, surface epithelium intact
5 Small- to medium-sized ulcer (<10 crypt widths)
6 Large ulcer (>10 crypt widths)
Infiltration with inflammatory cells (0–6)
Mucosa
0 None
1 Mild infiltration
2 Moderate infiltration
3 Severe infiltration
Submucosa
0 None
1 Mild to moderate infiltration and/or edema
2 Severe infiltration
Muscularis/serosa
0 Not involved
1 Involved
NOTE. Total score range was 0 to 12.
2020 Tregs Modify Response to a4b7 Inhibition 381Sciences, Hatfield, PA) and permeabilized with the Foxp3
transcription factor fixation/permeabilization kit (eBio-
science) before IL10, TGF-b1, and Foxp3 staining.Treg Suppression Assays
CD4þCD25- T cells (responder cells) were isolated from
spleens of C57BL/6 (CD45.1) WT mice by magnetic separa-
tion using the CD4þ T-cell negative isolation kit (BioLegend);
a biotin-conjugated anti-CD25 (PC61; BioLegend) antibody
was included to deplete Tregs. GFPþ Tregs were sorted with
a FACSAria 2 (BD Biosciences) from Itgb7þ/þFoxp3GFP or
Itgb7-/-Foxp3GFP mice. Responder cells were labeled with
CFSE and cocultured with Tregs (8:1, 4:1, 2:1, and 1:1 ratios)
in the presence of 5 mg/mL immobilized anti-CD3 (2C11) and
anti-CD28 (37.51) and IL2 for 4 days at 37C. The prolifera-
tion index was calculated by FlowJo v10.Table 2.Scoring Scheme for DSS Model
Intestinal architecture (0–3)
Epithelial changes
1 Focal erosions
2 Erosions
3 Erosions
Infiltration with inflammatory
cells (0–3)
Severity
1 Mild
2 Moderate
3 Marked
NOTE. Total score range was 0 to 6.In Vivo Competitive Lymphocyte Homing
The competitive homing assay used high- and low-dose
cell tracker, as described.53 GFPþ Tregs were sorted with
a FACSAria 2 (BD Biosciences) from Itgb7þ/þFoxp3GFP or
Itgb7-/-Foxp3GFP mice and labeled with 1 mmol/L and 10
mmol/L of eFluor670, resulting in readily discriminated cell
populations (Figure 14). Equal numbers of differentially
labeled Tregs (1  107) were mixed and then injected
intravenously into C57BL/6 recipient mice. Lymphoid or-
gans were harvested 3 hours after injection and isolated
cells were analyzed by flow cytometry. The ratio of Itgb7-/-
Tregs (10 mmol/L eFluor670) to Itgb7þ/þ Tregs (1 mmol/L
eFluor670) from different lymphoid organs are shown. For a
competitive homing assay of b7-deficient CD4þ T cells,
CD4þ T cells were isolated by the MojoSort mouse CD4 T-
cell isolation kit from Itgb7þ/þ or Itgb7-/- mice and labeled
with 1 mmol/L of CFSE and eFluor670, respectively.Mucosal architecture
± Focal ulcerations
Extended ulcerations ± granulation tissue ± pseudopolyps
Extent
Mucosa
Mucosa and submucosa
Transmural
10 10 104 5
6
10 10 104 5
6
WT-1M
Itgb7  -10M-/- WT-10M
Itgb7  -1M-/-
eFluor670 eFluor670
A B
Figure 14. Validation of dual-label intensity homing assay. (A) GFPþ Tregs were sorted with a FACSAria 2 (BD Biosciences)
from Itgb7þ/þFoxp3GFP or Itgb7-/-Foxp3GFP mice and labeled with 1 or 10 mmol/L of eFluor670, respectively. Equal numbers
(1 X 107) of differentially labeled Tregs were mixed and then injected intravenously into C57BL/6 recipient mice. Spleens were
harvested 3 hours after injection and isolated cells were analyzed by flow cytometry. The representative histograms were
gated on GFPþ Tregs. As shown in this histogram, this differential labeling produces 2 readily distinguished cell populations.
(B) The same experiment was performed as in panel A, with the cell types receiving each concentration of eFluor670 reversed,
that is, Itgb7þ/þFoxp3GFP (WT) or Itgb7-/-Foxp3GFP (Itgb7-/-) mice were labeled with 10 mmol/L or 1 mmol/L of eFluor670,
respectively.
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Total RNA was isolated from colon using a tissue ho-
mogenizer (JXFSTPRP-24; ThunderSci, Shanghai, China)
and TRIzol reagent according to the manufacturer’s pro-
tocol (Thermo Fisher Scientific, Waltham, MA). For gene
expression analysis, single-stranded complementary DNA
was produced from 10 mg colonic total RNA using Super-
Script III First-Strand synthesis and oligo-dT (deoxy-
thymine) primers according to the manufacturer’s protocol
(Thermo Fisher Scientific). The kappa SybrFast quantita-
tive PCR kit (Kapa Biosystems, Wilmington, MA) and
thermal cycler (CFX96 Real-Time System; Bio-Rad
Laboratories, Berkeley, CA) were used to determine the
relative levels of the genes analyzed (primer sequences areTable 3.Primers for Quantitative PCR
IL1b F
R
TNF-a F
R
IL6 F
R
IFNg F
R
IL17 F
R
GAPDH F
R
F, forward; GAPDH, glyceraldehyde-3-phosphate dehydrogenashown in Table 3) according to the manufacturer’s proto-
col. The 2–delta delta CT (-DDCT) method was used for
analysis, and data were normalized to glyceraldehyde-3-
phosphate dehydrogenase. Control values (WT mice or
Rag1-/- mice injected with phosphate-buffered saline) were
set to 1 for comparisons.Statistical Analysis
Statistical analysis was performed using PRISM software
(version 6.00, GraphPad Software, San Diego, CA), and all
data sets were checked for Gaussian normality distribution.
Data analysis was performed using a 2-tailed t test, 1-way or
2-way analysis of variance, followed by the BonferroniAGTGTGGATCCCAAGCAATAC
CTCCACTTTGCTCTTGACTTCT
AGTGACAAGCCTGTAGCCC
GAGGTTGACTTTCTCCTGGTAT
CTGCAAGAGACTTCCATCCAGTT
GAAGTAGGGAAGGCCGTGG
CTCTTCCTCATGGCTGTTTCT
TTCTTCCACATCTATGCCACTT
TCTCCACCGCAATGAAGACC
CACACCCACCAGCATCTTCT
CCAGGTTGTCTCCTGCGACTT
CCTGTTGCTGTAGCCGTATTCA
se; IFN, interferon; R, reverse; TNF, tumor necrosis factor.
2020 Tregs Modify Response to a4b7 Inhibition 383posttest as indicated in the figure legends. The resulting P
values are indicated as follows: *, .01< P < .05; **, .001< P
< .01; ***, P < .001. Plotted data are the means ± SEM of at
least 3 independent experiments.
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